An announcement from Valneva ( (VALN) ) is now available.
Valneva SE reported its financial results for 2024, showing a 13% increase in product sales and a 10% rise in total revenues compared to 2023. The company significantly reduced its net loss and operating cash burn, ending the year with a strong cash position of €168.3 million. Valneva made substantial clinical and regulatory progress, including the approval of its chikungunya vaccine in multiple regions and advancing its Lyme disease vaccine candidate. Looking ahead to 2025, Valneva anticipates continued revenue growth and strategic investments in R&D, supported by positive cash flows and a focus on expanding its vaccine portfolio.
More about Valneva
Valneva SE is a specialty vaccine company focusing on developing and commercializing vaccines for infectious diseases. Its primary products include vaccines for Japanese encephalitis, cholera, and the chikungunya virus. The company is also advancing a Lyme disease vaccine candidate and has a strong presence in Europe and North America.
YTD Price Performance: 42.58%
Average Trading Volume: 57,532
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $573.8M
For detailed information about VALN stock, go to TipRanks’ Stock Analysis page.